A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effi cacy and Safety of Idelalisib (GS-1101) in Combination with Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas

K Linton; MS Czuczman; H Knecht; R Auer; JJ McKendrick; NS Chua; G Collins; S De Vos; L Holes; E Abella; GA Salles

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effi cacy and Safety of Idelalisib (GS-1101) in Combination with Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas

K Linton, MS Czuczman, H Knecht, R Auer, JJ McKendrick, NS Chua, G Collins, S De Vos, L Holes, E Abella, GA Salles

Research output: Contribution to conference › Poster › peer-review

Original language	English
Publication status	Published - Jun 2014
Event	American Association for Cancer Research Annual Meeting - Chicago Duration: 1 Jan 1824 → …

Conference

Conference	American Association for Cancer Research Annual Meeting
City	Chicago
Period	1/01/24 → …

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Linton, K., Czuczman, MS., Knecht, H., Auer, R., McKendrick, JJ., Chua, NS., Collins, G., Vos, S. D., Holes, L., Abella, E., & Salles, GA. (2014). A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effi cacy and Safety of Idelalisib (GS-1101) in Combination with Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas. Poster session presented at American Association for Cancer Research Annual Meeting, Chicago.

@conference{553a1606e24741d991fdf32925467e60,

title = "A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effi cacy and Safety of Idelalisib (GS-1101) in Combination with Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas",

author = "K Linton and MS Czuczman and H Knecht and R Auer and JJ McKendrick and NS Chua and G Collins and Vos, {S De} and L Holes and E Abella and GA Salles",

year = "2014",

month = jun,

language = "English",

note = "American Association for Cancer Research Annual Meeting ; Conference date: 01-01-1824",

}

Linton, K, Czuczman, MS, Knecht, H, Auer, R, McKendrick, JJ, Chua, NS, Collins, G, Vos, SD, Holes, L, Abella, E & Salles, GA 2014, 'A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effi cacy and Safety of Idelalisib (GS-1101) in Combination with Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas', American Association for Cancer Research Annual Meeting, Chicago, 1/01/24.

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effi cacy and Safety of Idelalisib (GS-1101) in Combination with Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas. / Linton, K; Czuczman, MS; Knecht, H et al.
2014. Poster session presented at American Association for Cancer Research Annual Meeting, Chicago.

Research output: Contribution to conference › Poster › peer-review

TY - CONF

T1 - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effi cacy and Safety of Idelalisib (GS-1101) in Combination with Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas

AU - Linton, K

AU - Czuczman, MS

AU - Knecht, H

AU - Auer, R

AU - McKendrick, JJ

AU - Chua, NS

AU - Collins, G

AU - Vos, S De

AU - Holes, L

AU - Abella, E

AU - Salles, GA

PY - 2014/6

Y1 - 2014/6

M3 - Poster

T2 - American Association for Cancer Research Annual Meeting

Y2 - 1 January 1824

ER -

Linton K, Czuczman MS, Knecht H, Auer R, McKendrick JJ, Chua NS et al.. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effi cacy and Safety of Idelalisib (GS-1101) in Combination with Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas. 2014. Poster session presented at American Association for Cancer Research Annual Meeting, Chicago.